Literature DB >> 23364849

Ovarian cancer risk factors by tumor dominance, a surrogate for cell of origin.

Joanne Kotsopoulos1, Kathryn L Terry, Elizabeth M Poole, Bernard Rosner, Megan A Murphy, Jonathan L Hecht, Christopher P Crum, Stacey A Missmer, Daniel W Cramer, Shelley S Tworoger.   

Abstract

Differentiating ovarian tumors based on developmental pathway may further enhance our understanding of the disease. Traditionally, ovarian cancers were thought to arise from the ovarian surface epithelium; however, recent evidence suggests that some tumors originate in the fallopian tube. We classified cases in a population-based case-control study (New England Case-Control [NECC] Study) and two cohort studies (Nurses' Health Study [NHS]/Nurses' Health Study II [NHSII]) by tumor dominance, a proxy for tissue of origin. Dominant tumors (likely ovarian origin) are restricted to one ovary or are at least twice as large on one ovary compared to the other. Ovarian cancer risk factors were evaluated in relation to dominant and nondominant tumors (likely tubal origin) using polytomous logistic regression (NECC) or competing risks Cox models (NHS/NHSII). Results were combined using random-effects meta-analyses. Among 1,771 invasive epithelial ovarian cancer cases, we observed 1,089 tumors with a dominant mass and 682 with no dominant mass. Dominant tumors were more likely to be mucinous, endometrioid or clear cell, whereas nondominant tumors were more likely to be serous. Tubal ligation, two or more births, endometriosis and age were more strongly associated with dominant tumors (rate ratio [RR] = 0.60, 0.83, 1.58 and 1.37, respectively) than nondominant tumors (RR = 1.03, 0.93, 0.84 and 1.14, respectively; p-difference = 0.0001, 0.01, 0.0003 and 0.01, respectively). These data suggest that risk factors for tumors putatively arising from ovarian versus fallopian tube sites may differ; in particular, reproductive factors may be more important for ovarian-derived tumors. As this is the first study to evaluate ovarian cancer risk factors by tumor dominance, these results need to be validated by other studies.
Copyright © 2013 UICC.

Entities:  

Mesh:

Year:  2013        PMID: 23364849      PMCID: PMC3690361          DOI: 10.1002/ijc.28064

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  49 in total

Review 1.  Ovarian surface epithelium: biology, endocrinology, and pathology.

Authors:  N Auersperg; A S Wong; K C Choi; S K Kang; P C Leung
Journal:  Endocr Rev       Date:  2001-04       Impact factor: 19.871

Review 2.  Underlying mechanisms of ovarian cancer risk reduction after tubal ligation.

Authors:  David Cibula; Martin Widschwendter; Michael Zikan; Ladislav Dusek
Journal:  Acta Obstet Gynecol Scand       Date:  2011-04-15       Impact factor: 3.636

3.  C-reactive protein concentrations and subsequent ovarian cancer risk.

Authors:  Meghan A McSorley; Anthony J Alberg; Diane S Allen; Naomi E Allen; Louise A Brinton; Joanne F Dorgan; Michael Pollak; Yuzhen Tao; Kathy J Helzlsouer
Journal:  Obstet Gynecol       Date:  2007-04       Impact factor: 7.661

4.  Further evaluation of reproducibility and prognostic value of histologic typing and grading in FIGO stage I ovarian cancer patients without systemic locoregional adjuvant treatment.

Authors:  J. Brugghe; J.P.A. Baak; E. Wiltshaw; C. Fisher
Journal:  Int J Gynecol Cancer       Date:  1995-07       Impact factor: 3.437

5.  BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype?

Authors:  Ilana Cass; Christine Holschneider; Nandini Datta; Denise Barbuto; Ann E Walts; Beth Y Karlan
Journal:  Obstet Gynecol       Date:  2005-12       Impact factor: 7.661

6.  Reproductive risk factors for epithelial ovarian cancer according to histologic type and invasiveness.

Authors:  F Modugno; R B Ness; J E Wheeler
Journal:  Ann Epidemiol       Date:  2001-11       Impact factor: 3.797

7.  Reproductive factors and epithelial ovarian cancer risk by histologic type: a multiethnic case-control study.

Authors:  Ko-Hui Tung; Marc T Goodman; Anna H Wu; Katharine McDuffie; Lynne R Wilkens; Laurence N Kolonel; Abraham M Y Nomura; Keith Y Terada; Michael E Carney; Leslie H Sobin
Journal:  Am J Epidemiol       Date:  2003-10-01       Impact factor: 4.897

8.  Medication use and risk of ovarian carcinoma: a prospective study.

Authors:  James V Lacey; Mark E Sherman; Patricia Hartge; Arthur Schatzkin; Catherine Schairer
Journal:  Int J Cancer       Date:  2004-01-10       Impact factor: 7.396

9.  Use of nonsteroidal antiinflammatory agents and incidence of ovarian cancer in 2 large prospective cohorts.

Authors:  Simone P Pinheiro; Shelley S Tworoger; Daniel W Cramer; Bernard A Rosner; Susan E Hankinson
Journal:  Am J Epidemiol       Date:  2009-04-02       Impact factor: 4.897

10.  Different risk factor profiles for mucinous and nonmucinous ovarian cancer: results from the Danish MALOVA study.

Authors:  Marie Soegaard; Allan Jensen; Estrid Høgdall; Lise Christensen; Claus Høgdall; Jan Blaakaer; Susanne K Kjaer
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-06       Impact factor: 4.254

View more
  11 in total

1.  Menstrual pain and epithelial ovarian cancer risk.

Authors:  Ana Babic; Daniel W Cramer; Linda J Titus; Shelley S Tworoger; Kathryn L Terry
Journal:  Cancer Causes Control       Date:  2014-09-05       Impact factor: 2.506

Review 2.  Ovarian cancer.

Authors:  Ursula A Matulonis; Anil K Sood; Lesley Fallowfield; Brooke E Howitt; Jalid Sehouli; Beth Y Karlan
Journal:  Nat Rev Dis Primers       Date:  2016-08-25       Impact factor: 52.329

3.  The association between reproductive and hormonal factors and ovarian cancer by estrogen-α and progesterone receptor status.

Authors:  Amy L Shafrir; Megan S Rice; Mamta Gupta; Kathryn L Terry; Bernard A Rosner; Rulla M Tamimi; Jonathan L Hecht; Shelley S Tworoger
Journal:  Gynecol Oncol       Date:  2016-10-05       Impact factor: 5.482

4.  Ovarian cancer survival by tumor dominance, a surrogate for site of origin.

Authors:  Anna Ivanova; Anneli Loo; Shelley Tworoger; Christopher P Crum; Isabel Fan; John R McLaughlin; Barry Rosen; Harvey Risch; Steven A Narod; Joanne Kotsopoulos
Journal:  Cancer Causes Control       Date:  2015-03-13       Impact factor: 2.506

5.  Statistical methods for studying disease subtype heterogeneity.

Authors:  Molin Wang; Donna Spiegelman; Aya Kuchiba; Paul Lochhead; Sehee Kim; Andrew T Chan; Elizabeth M Poole; Rulla Tamimi; Shelley S Tworoger; Edward Giovannucci; Bernard Rosner; Shuji Ogino
Journal:  Stat Med       Date:  2015-12-01       Impact factor: 2.373

Review 6.  Through the glass darkly: intraepithelial neoplasia, top-down differentiation, and the road to ovarian cancer.

Authors:  Christopher P Crum; Michael Herfs; Gang Ning; Jonathan G Bijron; Brooke E Howitt; Cynthia A Jimenez; Suchanan Hanamornroongruang; Frank D McKeon; Wa Xian
Journal:  J Pathol       Date:  2013-12       Impact factor: 7.996

7.  Reproductive and Hormonal Factors and Risk of Ovarian Cancer by Tumor Dominance: Results from the Ovarian Cancer Cohort Consortium (OC3).

Authors:  Tianyi Huang; Mary K Townsend; Nicolas Wentzensen; Britton Trabert; Emily White; Alan A Arslan; Elisabete Weiderpass; Julie E Buring; Tess V Clendenen; Graham G Giles; I-Min Lee; Roger L Milne; N Charlotte Onland-Moret; Ulrike Peters; Dale P Sandler; Leo J Schouten; Piet A van den Brandt; Alicja Wolk; Anne Zeleniuch-Jacquotte; Shelley S Tworoger
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-11-12       Impact factor: 4.254

8.  Anti-Inflammatory Drug Use and Ovarian Cancer Risk by COX1/COX2 Expression and Infiltration of Tumor-Associated Macrophages.

Authors:  Mollie E Barnard; Jonathan L Hecht; Megan S Rice; Mamta Gupta; Holly R Harris; A Heather Eliassen; Bernard A Rosner; Kathryn L Terry; Shelley S Tworoger
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-10-30       Impact factor: 4.254

9.  Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium.

Authors:  Nicolas Wentzensen; Elizabeth M Poole; Britton Trabert; Emily White; Alan A Arslan; Alpa V Patel; V Wendy Setiawan; Kala Visvanathan; Elisabete Weiderpass; Hans-Olov Adami; Amanda Black; Leslie Bernstein; Louise A Brinton; Julie Buring; Lesley M Butler; Saioa Chamosa; Tess V Clendenen; Laure Dossus; Renee Fortner; Susan M Gapstur; Mia M Gaudet; Inger T Gram; Patricia Hartge; Judith Hoffman-Bolton; Annika Idahl; Michael Jones; Rudolf Kaaks; Victoria Kirsh; Woon-Puay Koh; James V Lacey; I-Min Lee; Eva Lundin; Melissa A Merritt; N Charlotte Onland-Moret; Ulrike Peters; Jenny N Poynter; Sabina Rinaldi; Kim Robien; Thomas Rohan; Dale P Sandler; Catherine Schairer; Leo J Schouten; Louise K Sjöholm; Sabina Sieri; Anthony Swerdlow; Anna Tjonneland; Ruth Travis; Antonia Trichopoulou; Piet A van den Brandt; Lynne Wilkens; Alicja Wolk; Hannah P Yang; Anne Zeleniuch-Jacquotte; Shelley S Tworoger
Journal:  J Clin Oncol       Date:  2016-06-20       Impact factor: 44.544

10.  Ovarian Cancer Risk Factor Associations by Primary Anatomic Site: The Ovarian Cancer Cohort Consortium.

Authors:  Shelley S Tworoger; Leo J Schouten; Renée T Fortner; Megan S Rice; Synnove F Knutsen; Michael J Orlich; Kala Visvanathan; Alpa V Patel; Mia M Gaudet; Anne Tjønneland; Marina Kvaskoff; Rudolf Kaaks; Antonia Trichopolou; Valeria Pala; N Charlotte Onland-Moret; Inger T Gram; Pilar Amiano; Annika Idahl; Naomi E Allen; Elisabete Weiderpass; Jenny N Poynter; Kim Robien; Graham G Giles; Roger L Milne; Veronica W Setiawan; Melissa A Merritt; Piet A van den Brandt; Anne Zeleniuch-Jacquotte; Alan A Arslan; Katie M O'Brien; Dale P Sandler; Alicja Wolk; Niclas Håkansson; Holly R Harris; Britton Trabert; Nicolas Wentzensen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-07-30       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.